Table 2.
Angiographic, functional, and safety outcomes of patients in the four studies included in the meta-analysis.
| Yang et al. (DIRECT-MT) | Zi et al. (DEVT) | Sukuzi et al. (SKIP) | Treurniet et al. (MR CLEAN NO IV) | |||||
|---|---|---|---|---|---|---|---|---|
| Treatment Arm | MT | MT±tPA | MT | MT±tPA | MT | MT±tPA | MT | MT±tPA |
| eTICI ≥ 2b | 243/306 (79.4%) | 267/316 (84.5%) | 100/116 (86.2%) | 102/118 (86.4%) | 91/101 (90.0%) | 96/103 (93.2%) | 214/273 (78.4%) | 221/266 (83.1%) |
| mRS 0–2 | 119/327 (36.4%) | 121/329 (36.8%) | 63/116 (54.3%) | 55/118 (46.6%) | 60/101 (59.4%) | 59/103 (57.3%) | 134/273 (49.1%) | 136/266 (51.1%) |
| Mortality | 58/327 (17.7%) | 62/329 (18.8%) | 20/116 (17.2%) | 21/118 (17.8% | 8/101 (7.9%) | 9/103 (8.7%) | 56/273 (20.5%) | 42/266 (15.8%) |
| sICH | 14/327 (4.3%) | 16/329 (4.9%) | 7/115 (6.1%) | 8/117 (6.8%) | 6/101 (5.9%) | 8/103 (7.8%) | 16/273 (5.9%) | 14/266 (5.3%) |
| Distal Emboli | 35/327 (10.7%) | 31/329 (9.4%) | 19/113 (16.8%) | 21/117 (17.9%) | N/A | N/A | N/A | N/A |